Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 23

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 23
---
 thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors.

The members of our nominating and corporate governance committee are Wendell Wierenga, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, and Stephanie S. Okey, M.S. Dr. Wierenga serves as the chair of the committee. The nominating and corporate governance committee met three times during fiscal year 2024. Our board has determined that each of Dr. Wierenga, Dr. Bedrosian, Ms. Deardorf, and Ms. Okey is independent under the applicable rules and regulations of Nasdaq relating to nominating and corporate governance committee independence. The nominating and corporate governance committee operates under a written charter, which the nominating and corporate governance committee reviews and evaluates at least annually.

Research and Development Committee

The research and development committee is responsible for, among other things, advising and assisting our board of directors in developing our research and development strategy, reviewing and evaluating our long-term strategic goals and objectives, as well as progress, of our research and development programs, reviewing and evaluating the resources we make available for our research and development activities and our investment in our research, development and technology programs, and advising on scientific matters involving the safety and effectiveness of the Company’s drug candidates.

The members of our research and development committee are Camille L. Bedrosian, M.D., Weston Nichols, Ph.D., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D. Dr. Bedrosian serves as the chair of the committee. The research and development committee met four times during fiscal year 2024. The research and development committee operates under a written charter, which the research and development committee will review and evaluate from time to time.

Global Therapeutics Strategy and Access Committee

The global therapeutics strategy and access committee is responsible for, among other things, advising and assisting our board of directors on oversight, evaluation and guidance regarding the Company’s overall investment in and strategic direction with respect to the Company’s product commercialization efforts and providing strategic and operational advice to the Company’s prioritization decisions regarding the allocation, deployment, utilization of and investment in the Company’s products and advancement of therapeutics strategy and operations.

The members of our global therapeutics strategy and access committee are Rogério Vival